{"id":"https://openalex.org/W2913981973","doi":"https://doi.org/10.1182/blood-2018-99-116895","title":"Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies","display_name":"Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2913981973","doi":"https://doi.org/10.1182/blood-2018-99-116895","mag":"2913981973"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-116895","doi":"https://doi.org/10.1182/blood-2018-99-116895","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-116895","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103625130","display_name":"Sara N. Morrow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sara Morrow","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022845334","display_name":"Dennis Dobrovolsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dennis Dobrovolsky","raw_affiliation_strings":["Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100746977","display_name":"Eric W. Wang","orcid":"https://orcid.org/0000-0002-1180-5854","observed_orcids":["https://orcid.org/0000-0002-1180-5854"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric Wang","raw_affiliation_strings":["Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080294108","display_name":"Rados\u0142aw P. Nowak","orcid":"https://orcid.org/0000-0002-0605-0071","observed_orcids":["https://orcid.org/0000-0002-0605-0071"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rados\u0142aw P. Nowak","raw_affiliation_strings":["Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010207791","display_name":"Katherine A. Donovan","orcid":"https://orcid.org/0000-0002-8539-5106","observed_orcids":["https://orcid.org/0000-0002-8539-5106"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Katherine Donovan","raw_affiliation_strings":["Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109482718","display_name":"Tyler B. Faust","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Tyler Faust","raw_affiliation_strings":["Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089994476","display_name":"Guang Yang","orcid":"https://orcid.org/0000-0003-3049-4200","observed_orcids":["https://orcid.org/0000-0003-3049-4200"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guang Yang","raw_affiliation_strings":["Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Inst., Boston, MA","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Inst., Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024858492","display_name":"Zhengnian Li","orcid":"https://orcid.org/0000-0001-5851-8011","observed_orcids":["https://orcid.org/0000-0001-5851-8011"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Zhengnian Li","raw_affiliation_strings":["Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006261099","display_name":"Eric S. Fischer","orcid":"https://orcid.org/0000-0001-7337-6306","observed_orcids":["https://orcid.org/0000-0001-7337-6306"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric Fischer","raw_affiliation_strings":["Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081299017","display_name":"Steven Peter Treon","orcid":"https://orcid.org/0000-0001-6393-6154","observed_orcids":["https://orcid.org/0000-0001-6393-6154"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven P Treon","raw_affiliation_strings":["Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026688095","display_name":"David M. Weinstock","orcid":"https://orcid.org/0000-0002-8724-3907","observed_orcids":["https://orcid.org/0000-0002-8724-3907"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M Weinstock","raw_affiliation_strings":["Broad Institute of Harvard and MIT, Boston, MA","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Broad Institute of Harvard and MIT, Boston, MA","institution_ids":["https://openalex.org/I107606265"]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022352605","display_name":"Nathanael S. Gray","orcid":"https://orcid.org/0000-0001-5354-7403","observed_orcids":["https://orcid.org/0000-0001-5354-7403"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nathanael S. Gray","raw_affiliation_strings":["Biological Chemistry & Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Chemistry & Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5006261099","https://openalex.org/A5010207791","https://openalex.org/A5022352605","https://openalex.org/A5022845334","https://openalex.org/A5024858492","https://openalex.org/A5080294108","https://openalex.org/A5100746977","https://openalex.org/A5103625130","https://openalex.org/A5109482718"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"263","last_page":"263"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.989300012588501,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.989300012588501,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.009800000116229057,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase","display_name":"Bruton's tyrosine kinase","score":0.9800000190734863},{"id":"https://openalex.org/keywords/ikzf1","display_name":"IKZF1","score":0.7609999775886536},{"id":"https://openalex.org/keywords/ikzf3","display_name":"IKZF3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.7080000042915344},{"id":"https://openalex.org/keywords/cereblon","display_name":"cereblon","score":0.44200000166893005},{"id":"https://openalex.org/keywords/e3-ubiquitin-ligase","display_name":"E3 ubiquitin ligase","score":0.718999981880188},{"id":"https://openalex.org/keywords/ibrutinib-resistance","display_name":"ibrutinib resistance","score":0.8410000205039978},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":0.7310000061988831},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.7070000171661377},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.890999972820282}],"concepts":[{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.9840508699417114},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.9409732818603516},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5887309312820435},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.5860569477081299},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.555856466293335},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5459673404693604},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3363964259624481},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3085256516933441},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.22644835710525513},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.21816176176071167},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.20825818181037903},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.20216155052185059},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19494760036468506}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-116895","doi":"https://doi.org/10.1182/blood-2018-99-116895","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-116895","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7400000095367432,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2905558559","https://openalex.org/W2987829429","https://openalex.org/W7165779915","https://openalex.org/W4409631103","https://openalex.org/W4362593786","https://openalex.org/W4403304238","https://openalex.org/W4385667176","https://openalex.org/W4310106669","https://openalex.org/W3095525735","https://openalex.org/W7148654332"],"abstract_inverted_index":{"Abstract":[0],"Bruton's":[1],"Tyrosine":[2],"Kinase":[3],"(BTK),":[4],"a":[5,11,29,101,135,152,184,190,209,397,433,445],"TEC-family":[6],"non-receptor":[7],"tyrosine":[8],"kinase,":[9],"plays":[10],"critical":[12],"role":[13],"in":[14,114,254,360,388,418,448,481],"B-cell":[15,34],"development":[16],"and":[17,47,122,165,201,244,246,258,303,308,363,409,421,475],"function.":[18],"Targeting":[19],"of":[20,66,97,127,151,154,176,204,242,272,290,293,299,385,426,490],"BTK":[21,62,91,98,119,173,205,216,243,261,276,294,359,377,402,477],"with":[22,314,323,333,350,376,463,479],"covalent":[23,61],"inhibitors":[24],"like":[25],"ibrutinib":[26,71,373,464],"has":[27],"become":[28],"standard":[30],"approach":[31],"for":[32,73,83,163,280,295,494],"many":[33,53],"malignancies,":[35],"including":[36],"chronic":[37],"lymphocytic":[38],"leukemia":[39],"(CLL),":[40],"Waldenstrom":[41],"macroglobulinemia,":[42],"mantle":[43],"cell":[44,419],"lymphoma":[45,50],"(MCL)":[46],"marginal":[48],"zone":[49],"(MZL).":[51],"Yet,":[52],"patients":[54,67],"demonstrate":[55],"intrinsic":[56],"or":[57,75,229,316,325,357,465],"acquired":[58],"resistance":[59,88,374],"to":[60,89,104,134,148,189,221,344,461],"inhibition.":[63],"The":[64,428],"prognosis":[65],"who":[68,435],"relapse":[69],"after":[70,282],"treatment":[72,462],"MCL":[74,389,485,495],"CLL":[76],"is":[77,174,396],"dismal,":[78],"highlighting":[79],"the":[80,117,149,158,177,214,251,328,334,383,386,488],"urgent":[81],"need":[82],"new":[84],"approaches":[85],"that":[86,95,141,157,172,237,285,339,370,394,486],"overcome":[87],"current":[90],"inhibitors.":[92],"We":[93,169,197,354],"hypothesized":[94],"degradation":[96,139,405,489],"could":[99],"be":[100,161,342],"better":[102],"alternative":[103],"inhibition":[105],"alone,":[106],"as":[107,208,265,267,310,318,320,399],"it":[108,340,400],"would":[109,341],"both:":[110],"1)":[111],"maintain":[112],"efficacy":[113,416],"cells":[115,362],"harboring":[116],"ibrutinib-resistant":[118],"C418S":[120],"mutation":[121],"2)":[123],"target":[124,153,159],"non-catalytic":[125],"functions":[126],"BTK.":[128],"To":[129,211],"address":[130],"this,":[131],"we":[132,249,381,412,471],"turned":[133],"small":[136],"molecule-mediated":[137],"protein":[138],"platform":[140],"utilizes":[142],"an":[143,296,351,365,452],"E3":[144],"ligase-targeting":[145],"moiety":[146],"linked":[147,188,220],"ligand":[150],"interest,":[155],"so":[156],"can":[160],"marked":[162],"ubiquitination":[164],"subsequent":[166],"proteasomal":[167],"degradation.":[168],"previously":[170,347],"showed":[171,369,393],"one":[175],"most":[178],"robustly":[179],"degraded":[180],"kinase":[181,186],"targets":[182],"using":[183,206,223],"nonspecific":[185],"inhibitor":[187,217,336],"imide-based":[191],"core":[192],"followed":[193],"by":[194,312],"agnostic":[195],"proteomics.":[196],"synthesized":[198],"highly":[199,473],"potent":[200,474],"selective":[202,476],"degraders":[203,239,287,329,387,478],"imides":[207],"base.":[210],"do":[212],"so,":[213],"parent":[215],"CGI1746":[218],"was":[219,430],"thalidomide":[222],"either":[224],"polyethylene":[225],"glycol":[226],"(DD-03-007)":[227],"linkers":[228],"saturated":[230],"hydrocarbon":[231],"chain":[232],"(DD-03-171)":[233],"linkers.":[234],"After":[235],"verifying":[236],"these":[238,286],"induce":[240,487],"dimerization":[241],"CRBN":[245],"penetrate":[247],"cells,":[248],"explored":[250,382],"pharmacological":[252],"effects":[253,384],"vitro.":[255],"Both":[256],"DD-03-007":[257,302,371],"DD-03-171":[259,304,395,443,455],"reduced":[260],"levels":[262,277],"at":[263,451],"concentrations":[264],"low":[266,279],"40":[268],"nM":[269],"within":[270],"4h":[271],"treatment.":[273],"Furthermore,":[274],"cellular":[275],"remained":[278],"24h":[281],"washout,":[283],"showing":[284],"are":[288,305],"capable":[289],"sustaining":[291],"depletion":[292],"extended":[297,458],"period":[298],"time":[300],"(Figure).":[301,468],"both":[306,441],"ligase":[307],"proteasome-dependent,":[309],"shown":[311],"co-treatment":[313],"bortezomib":[315],"MLN-4924":[317],"well":[319],"competition":[321],"experiments":[322],"lenalidomide":[324,466],"CGI-1746.":[326],"Moreover,":[327],"exhibited":[330],"strong":[331],"synergy":[332],"HCK":[335,352],"A419259,":[337],"suggesting":[338],"possible":[343],"recapitulate":[345],"ibrutinib's":[346],"reported":[348],"polypharmacology":[349],"inhibitor.":[353],"overexpressed":[355],"wild-type":[356],"C481S":[358,378],"TMD-8":[361],"ran":[364],"antiproliferation":[366],"assay,":[367],"which":[368],"overcame":[372],"associated":[375],"mutation.":[379],"Next,":[380],"specifically.":[390],"Proteomic":[391],"analysis":[392],"triple-degrader,":[398],"degrades":[401],"but":[403],"retains":[404],"activity":[406,480],"on":[407,438],"IKZF1":[408],"IKZF3.":[410],"Finally,":[411],"performed":[413],"In":[414,440,469],"vivo":[415,482],"studies":[417],"line":[420],"patient-derived":[422],"xenograft":[423],"(PDX)":[424],"models":[425],"MCL.":[427],"latter":[429],"obtained":[431],"from":[432],"patient":[434],"had":[436],"progressed":[437],"ibrutinib.":[439],"models,":[442],"caused":[444],"significant":[446],"reduction":[447],"tumor":[449],"burden":[450],"early":[453],"timepoint.":[454],"also":[456],"markedly":[457],"survival":[459],"compared":[460],"alone":[467],"conclusion,":[470],"developed":[472],"against":[483],"human":[484],"multiple":[491],"factors":[492],"essential":[493],"survival.":[496],"Figure.":[497,498],"Disclosures":[499],"Treon:":[500],"Pharmacyclics:":[501],"Consultancy,":[502,510,529],"Other:":[503,511],"Travel,":[504,512],"Accommodations,":[505,513],"Expenses,":[506],"Research":[507,520,530,541],"Funding;":[508,531,542],"Janssen:":[509],"Expenses;":[514],"Johnson":[515],"&":[516,555],"Johnson:":[517],"Consultancy;":[518,527,545],"BMS:":[519],"Funding.":[521],"Weinstock:Novartis,":[522],"Dragonfly,":[523],"Travera,":[524],"DxTerity,":[525],"Travera:":[526,557],"Novartis:":[528],"Novartis,":[532],"Astra":[533,546],"Zeneca,":[534,547],"Abbvie,":[535],"Aileron,":[536],"Surface":[537],"Oncology,":[538],"Daiichi":[539],"Sankyo:":[540],"Genentech/Roche,":[543],"Monsanto:":[544],"JAX,":[548],"Samumed,":[549],"Regeneron,":[550],"Sun":[551],"Pharma,":[552],"Prescient:":[553],"Patents":[554],"Royalties;":[556],"Equity":[558,565],"Ownership.":[559,566],"Gray:Syros,":[560],"Soltego,":[561],"Petra,":[562],"C4":[563],"Therapeutics:":[564]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2019-02-21T00:00:00"}